NCT02694822: AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers

NCT02694822
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: History of or active metastases from non-CNS tumors
https://ClinicalTrials.gov/show/NCT02694822

Comments are closed.

Up ↑